Mainstay Medical publishes 2017 full year results

Dublin, Ireland: 15 February 2018 - Mainstay Medical International plc (Euronext Paris: MSTY.PA and ESM of the Irish Stock Exchange: MSTY.IE), a medical device company focused on bringing to market ReActiv8, an implantable restorative neuro-stimulation system to treat disabling Chronic Low Back Pain, announces today the publication of its 2017 Full Year results and Annual Report.

More info on Mainstay Medical's website.


Next > Mainstay Medical announces 30 million financing new capital to complete US Pivotal ReActiv8-B clinical study and advance european commercialization

Previous > FEops Elects Tom Fleming to its Board of Directors